Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Variants at the 9p21 locus and melanoma risk

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

The influence of variants at the 9p21 locus on melanoma risk has been reported through investigation of CDKN2A variants through candidate gene approach as well as by genome wide association studies (GWAS).

Methods

In the present study we genotyped, 25 SNPs that tag 273 variants on chromosome 9p21 in 837 melanoma cases and 1154 controls from Spain. Ten SNPs were selected based on previous associations, reported in GWAS, with either melanocytic nevi or melanoma risk or both. The other 15 SNPs were selected to fine map the CDKN2A gene region.

Results

All the 10 variants selected from the GWAS showed statistically significant association with melanoma risk. Statistically significant association with melanoma risk was also observed for the carriers of the variant T-allele of rs3088440 (540 C>T) at the 3’ UTR of CDKN2A gene with an OR 1.52 (95% CI 1.14-2.04). Interaction analysis between risk associated polymorphisms and previously genotyped MC1R variants, in the present study, did not show any statistically significant association. Statistical significant association was observed for the interaction between phototypes and the rs10811629 (located in intron 5 of MTAP). The strongest association was observed between the homozygous carrier of the A–allele and phototype II with an OR of 15.93 (95% CI 5.34-47.54).

Conclusions

Our data confirmed the association of different variants at chromosome 9p21 with melanoma risk and we also found an association of a variant with skin phototypes.
Appendix
Available only for authorised users
Literature
1.
Garbe C, Blum A: Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol. 2001, 14 (5): 280-290. 10.1159/000056358.CrossRefPubMed
2.
Berwick M, Wiggins C: The current epidemiology of cutaneous malignant melanoma. Front Biosci. 2006, 11: 1244-1254. 10.2741/1877.CrossRefPubMed
3.
Maddodi N, Setaluri V: Role of UV in cutaneous melanoma. Photochem Photobiol. 2008, vol. 84 (2008/02/06 edn): 528-536.CrossRef
4.
Gallagher RP, Spinelli JJ, Lee TK: Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2005, 14 (3): 562-566. 10.1158/1055-9965.EPI-04-0564.CrossRefPubMed
5.
6.
Han J, Colditz GA, Hunter DJ: Risk factors for skin cancers: a nested case–control study within the Nurses’ health study. Int J Epidemiol. 2006, 35 (6): 1514-1521. 10.1093/ije/dyl197.CrossRefPubMed
7.
Hansson J: Familial cutaneous melanoma. Adv Exp Med Biol. 2010, 685: 134-145. 10.1007/978-1-4419-6448-9_13.CrossRefPubMed
8.
Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JA, Pastinen T, Cervino A, Zhao ZZ, Deloukas P, Soranzo N, et al: Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet. 2009, 41 (8): 915-919. 10.1038/ng.410.CrossRefPubMed
9.
Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, Randerson-Moor J, Aitken JF, Avril MF, Azizi E, et al: Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet. 2009, 41 (8): 920-925. 10.1038/ng.411.CrossRefPubMedPubMedCentral
10.
Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, Zhang M, Qureshi AA, Vattathil S, et al: Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet. 2011, 20 (24): 5012-5023. 10.1093/hmg/ddr415.CrossRefPubMedPubMedCentral
11.
Macgregor S, Montgomery GW, Liu JZ, Zhao ZZ, Henders AK, Stark M, Schmid H, Holland EA, Duffy DL, Zhang M, et al: Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet. 2011, 43 (11): 1114-1118. 10.1038/ng.958.CrossRefPubMedPubMedCentral
12.
Barrett JH, Iles MM, Harland M, Taylor JC, Aitken JF, Andresen PA, Akslen LA, Armstrong BK, Avril MF, Azizi E, et al: Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet. 2011, 43 (11): 1108-1113. 10.1038/ng.959.CrossRefPubMedPubMedCentral
13.
Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N: CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst. 1999, 91 (5): 446-452. 10.1093/jnci/91.5.446.CrossRefPubMed
14.
Kumar R, Smeds J, Berggren P, Straume O, Rozell BL, Akslen LA, Hemminki K: A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int J Cancer. 2001, 95 (6): 388-393. 10.1002/1097-0215(20011120)95:6<388::AID-IJC1069>3.0.CO;2-6.CrossRefPubMed
15.
Debniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Debniak B, Zaluga E, Maleszka R, Kladny J, Gorski B, et al: CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res. 2005, 65 (3): 835-839.PubMed
16.
Ibarrola-Villava M, Fernandez LP, Pita G, Bravo J, Floristan U, Sendagorta E, Feito M, Aviles JA, Martin-Gonzalez M, Lazaro P, et al: Genetic analysis of three important genes in pigmentation and melanoma susceptibility: CDKN2A, MC1R and HERC2/OCA2. Exp Dermatol. 2010, 19 (9): 836-844. 10.1111/j.1600-0625.2010.01115.x.CrossRefPubMed
17.
Chatzinasiou F, Lill CM, Kypreou K, Stefanaki I, Nicolaou V, Spyrou G, Evangelou E, Roehr JT, Kodela E, Katsambas A, et al: Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst. 2011, 103 (16): 1227-1235. 10.1093/jnci/djr219.CrossRefPubMedPubMedCentral
18.
Scherer D, Nagore E, Bermejo JL, Figl A, Botella-Estrada R, Thirumaran RK, Angelini S, Hemminki K, Schadendorf D, Kumar R: Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations. Int J Cancer. 2009, 125 (8): 1868-1875. 10.1002/ijc.24548.CrossRefPubMed
19.
Maccioni L, Rachakonda PS, Scherer D, Bermejo JL, Planelles D, Requena C, Hemminki K, Nagore E, Kumar R: Variants at chromosome 20 (ASIP locus) and melanoma risk. Int J Cancer. 2013, 132 (1): 42-54. 10.1002/ijc.27648.CrossRefPubMed
20.
Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, Simon M, Marie Y, Boisselier B, Delattre JY, et al: Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009, 41 (8): 899-904. 10.1038/ng.407.CrossRefPubMedPubMedCentral
21.
Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, Ballman KV, Berger M, Buckner JC, Chang S, et al: Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009, 41 (8): 905-908. 10.1038/ng.408.CrossRefPubMedPubMedCentral
22.
Saxena R, Voight BF, Lyssenko V, Burtt NP, De Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, et al: Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007, 316 (5829): 1331-1336.CrossRefPubMed
23.
Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, et al: A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007, 316 (5829): 1341-1345. 10.1126/science.1142382.CrossRefPubMedPubMedCentral
24.
Timpson NJ, Lindgren CM, Weedon MN, Randall J, Ouwehand WH, Strachan DP, Rayner NW, Walker M, Hitman GA, Doney AS, et al: Adiposity-related heterogeneity in patterns of type 2 diabetes susceptibility observed in genome-wide association data. Diabetes. 2009, 58 (2): 505-510.CrossRefPubMedPubMedCentral
25.
Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, De Bakker PI, Abecasis GR, Almgren P, Andersen G, et al: Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008, 40 (5): 638-645. 10.1038/ng.120.CrossRefPubMedPubMedCentral
26.
Takeuchi F, Serizawa M, Yamamoto K, Fujisawa T, Nakashima E, Ohnaka K, Ikegami H, Sugiyama T, Katsuya T, Miyagishi M, et al: Confirmation of multiple risk Loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese population. Diabetes. 2009, 58 (7): 1690-1699. 10.2337/db08-1494.CrossRefPubMedPubMedCentral
27.
Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G, et al: Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010, 42 (7): 579-589. 10.1038/ng.609.CrossRefPubMedPubMedCentral
28.
Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, Masson G, et al: A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007, 316 (5830): 1491-1493. 10.1126/science.1142842.CrossRefPubMed
29.
Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR, Stanulla M, Schrappe M, et al: Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet. 2010, 42 (6): 492-494. 10.1038/ng.585.CrossRefPubMedPubMedCentral
30.
Stacey SN, Sulem P, Masson G, Gudjonsson SA, Thorleifsson G, Jakobsdottir M, Sigurdsson A, Gudbjartsson DF, Sigurgeirsson B, Benediktsdottir KR, et al: New common variants affecting susceptibility to basal cell carcinoma. Nat Genet. 2009, 41 (8): 909-914. 10.1038/ng.412.CrossRefPubMedPubMedCentral
31.
Larson MG, Atwood LD, Benjamin EJ, Cupples LA, D’Agostino RB, Fox CS, Govindaraju DR, Guo CY, Heard-Costa NL, Hwang SJ, et al: Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med Genet. 2007, 8 (Suppl 1): S5-10.1186/1471-2350-8-S1-S5.CrossRefPubMedPubMedCentral
32.
Kvaskoff M, Whiteman DC, Zhao ZZ, Montgomery GW, Martin NG, Hayward NK, Duffy DL: Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma. Twin research and human genetics : the official journal of the International Society for Twin Studies. 2011, 14 (5): 422-432. 10.1375/twin.14.5.422.CrossRef
33.
Behrmann I, Wallner S, Komyod W, Heinrich PC, Schuierer M, Buettner R, Bosserhoff AK: Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol. 2003, 163 (2): 683-690. 10.1016/S0002-9440(10)63695-4.CrossRefPubMedPubMedCentral
34.
Stevens AP, Spangler B, Wallner S, Kreutz M, Dettmer K, Oefner PJ, Bosserhoff AK: Direct and tumor microenvironment mediated influences of 5'-deoxy-5'-(methylthio)adenosine on tumor progression of malignant melanoma. J Cell Biochem. 2009, 106 (2): 210-219. 10.1002/jcb.21984.CrossRefPubMed
35.
Mowen KA, Tang J, Zhu W, Schurter BT, Shuai K, Herschman HR, David M: Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell. 2001, 104 (5): 731-741. 10.1016/S0092-8674(01)00269-0.CrossRefPubMed
36.
Wild PJ, Meyer S, Landthaler M, Hofstaedter F, Bosserhoff AK: A potential predictive marker for response to interferon in malignant melanoma. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG. 2007, 5 (6): 456-459. 10.1111/j.1610-0387.2007.06303.x.CrossRefPubMed
37.
Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, et al: Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet. 2010, 42 (6): 504-507. 10.1038/ng.586.CrossRefPubMedPubMedCentral
38.
Folkersen L, Kyriakou T, Goel A, Peden J, Malarstig A, Paulsson-Berne G, Hamsten A, Hugh W, Franco-Cereceda A, Gabrielsen A, et al: Relationship between CAD risk genotype in the chromosome 9p21 locus and gene expression. Identification of eight new ANRIL splice variants. PLoS One. 2009, 4 (11): e7677-10.1371/journal.pone.0007677.CrossRefPubMedPubMedCentral
39.
Pasmant E, Sabbagh A, Vidaud M, Bieche I: ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 2011, 25 (2): 444-448. 10.1096/fj.10-172452.CrossRefPubMed
40.
Sato K, Nakagawa H, Tajima A, Yoshida K, Inoue I: ANRIL is implicated in the regulation of nucleus and potential transcriptional target of E2F1. Oncol Rep. 2010, 24 (3): 701-707.PubMed
41.
Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, Xiong Y: Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 2011, 30 (16): 1956-1962. 10.1038/onc.2010.568.CrossRefPubMed
42.
Spica T, Portela M, Gerard B, Formicone F, Descamps V, Crickx B, Ollivaud L, Archimbaud A, Dupin N, Wolkenstein P, et al: The A148T variant of the CDKN2A gene is not associated with melanoma risk in the French and Italian populations. J Invest Dermatol. 2006, 126 (7): 1657-1660. 10.1038/sj.jid.5700293.CrossRefPubMed
43.
Pjanova D, Engele L, Randerson-Moor JA, Harland M, Bishop DT, Newton Bishop JA, Taylor C, Debniak T, Lubinski J, Kleina R, et al: CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population. Melanoma Res. 2007, 17 (3): 185-191. 10.1097/CMR.0b013e328014a2cd.CrossRefPubMed
44.
Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T, Bjorklund M, Wei G, Yan J, Niittymaki I, et al: The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet. 2009, 41 (8): 885-890. 10.1038/ng.406.CrossRefPubMed
45.
Visser M, Kayser M, Palstra RJ: HERC2 rs12913832 modulates human pigmentation by attenuating chromatin-loop formation between a long-range enhancer and the OCA2 promoter. Genome Res. 2012, 22 (3): 446-455. 10.1101/gr.128652.111.CrossRefPubMedPubMedCentral
46.
Cooper DN: Functional intronic polymorphisms: buried treasure awaiting discovery within our genes. Hum Genomics. 2010, 4 (5): 284-288. 10.1186/1479-7364-4-5-284.CrossRefPubMedPubMedCentral
47.
48.
Bloethner S, Scherer D, Drechsel M, Hemminki K, Kumar R: Malignant melanoma–a genetic overview. Actas Dermosifiliogr. 2009, 100 (Suppl 1): 38-51.CrossRefPubMed
49.
Chin L: The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer. 2003, 3 (8): 559-570. 10.1038/nrc1145.CrossRefPubMed
50.
Ruas M, Peters G: The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1998, 1378 (2): F115-177.PubMed
51.
Latres E, Malumbres M, Sotillo R, Martin J, Ortega S, Martin-Caballero J, Flores JM, Cordon-Cardo C, Barbacid M: Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J. 2000, 19 (13): 3496-3506. 10.1093/emboj/19.13.3496.CrossRefPubMedPubMedCentral
Metadata
Title
Variants at the 9p21 locus and melanoma risk
Publication date
01-12-2013
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-325

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis

Research article

A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo

Research article

Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer

Study protocol

“EXHALE”: exercise as a strategy for rehabilitation in advanced stage lung cancer patients: a randomized clinical trial comparing the effects of 12 weeks supervised exercise intervention versus usual care for advanced stage lung cancer patients

Research article

Reduced mrna expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer

Research article

Antioxidant-mediated up-regulation of OGG1 via NRF2 induction is associated with inhibition of oxidative DNA damage in estrogen-induced breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits